Venegas M, Villanueva RA, González K, Brahm J. IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients. World J Gastroenterol 2011; 17(31): 3636-3639 [PMID: 21987611 DOI: 10.3748/wjg.v17.i31.3636]
Corresponding Author of This Article
Dr. Mauricio Venegas, Sección de Gastroenterología, Departamento de Medicina, Hospital Clínico Universidad de Chile, Avda, Santos Dumont 999, Independencia, 8340457 Santiago, Chile. mvenegas@redclinicauchile.cl
Article-Type of This Article
Brief Article
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Aug 21, 2011; 17(31): 3636-3639 Published online Aug 21, 2011. doi: 10.3748/wjg.v17.i31.3636
IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients
Mauricio Venegas, Rodrigo A Villanueva, Katherine González, Javier Brahm
Mauricio Venegas, Katherine González, Javier Brahm, Centro de Estudios Avanzados de las Hepatitis Virales, Sección de Gastroenterología, Departamento de Medicina, Hospital Clínico Universidad de Chile, 8340457 Santiago, Chile
Rodrigo A Villanueva, Centro de Estudios Avanzados de las Hepatitis Virales, Laboratorio de Virus Hepatitis, Programa de Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de Chile, 8340457 Santiago, Chile
Author contributions: González K and Brahm J were responsible for study concept and design, acquisition of data, drafting, and critical revision of the manuscript for intellectual content; Venegas M and Villanueva RA were responsible for acquisition and interpretation of data, drafting the article, study concept and design, acquisition of data, drafting, and critical revision of the manuscript for intellectual content.
Supported by The grant OAIC 394/10 (to M.V.) from Hospital Clínico Universidad de Chile
Correspondence to: Dr. Mauricio Venegas, Sección de Gastroenterología, Departamento de Medicina, Hospital Clínico Universidad de Chile, Avda, Santos Dumont 999, Independencia, 8340457 Santiago, Chile. mvenegas@redclinicauchile.cl
Telephone: +562-978-8348 Fax: +562-978-8348
Received: December 4, 2010 Revised: February 15, 2011 Accepted: February 22, 2011 Published online: August 21, 2011
Abstract
AIM: To analyze the association of three IL28B single nucleotide polymorphisms with response to therapy in Chilean patients infected with hepatitis C virus (HCV).
METHODS: We studied two groups of patients with chronic HCV infection (genotype 1), under standard combined treatment with pegylated interferon plus ribavirin. One group consisted of 50 patients with sustained virological response, whereas the second group consisted of 49 null responders. In order to analyze the IL28B single nucleotide polymorphisms rs12979860, rs12980275 and rs8099917, samples were used for polymerase chain reaction amplification, and the genotyping was performed by restriction fragment length polymorphism.
RESULTS: The IL28B rs12979860 CC, rs12980275 AA and rs8099917 TT genotypes were much more frequently found in patients with sustained virological response compared to null responders (38%, 44% and 50% vs 2%, 8.2% and 8.2%, respectively). These differences were highly significant in all three cases (P < 0.0001).
CONCLUSION: The three IL28B polymorphisms studied are strongly associated with sustained virological response to therapy in Chilean patients with chronic HCV (genotype 1).
